HDAC2 and neoplasm: Using a high-throughput drug screening of patient-derived tumor organoids, Kluiver et al. found that the embryonal tumor organoids and fetal tumor organoids are highly and equally sensitive to HDAC2 inhibitors, which is consistent with findings from a recent study by Espinoza et al. [54].